Tetrodotoxin clinical trials
Also written TTX.
How each study uses Tetrodotoxin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Wex Pharmaceuticals Inc. (6) · Dogwood Therapeutics Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Local anesthetics source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Tetrodotoxin.
- Dec 2026Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainPhase 2 · Dogwood Therapeutics Inc.
Studies
Open first, then newest update. How each study uses Tetrodotoxin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainActive, not recruitingPhase 2Dogwood Therapeutics Inc.NCT06848348Written as Halneuron
- A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic PainTerminatedPhase 2Wex Pharmaceuticals Inc.NCT05359133Written as Tetrodotoxin
- A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult SubjectsCompletedPhase 1Wex Pharmaceuticals Inc.NCT04083833Written as Tetrodotoxin
- The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy TreatmentTerminatedPhase 2Wex Pharmaceuticals Inc.NCT01655823Written as Tetrodotoxin
- Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related PainCompletedPhase 3Wex Pharmaceuticals Inc.NCT00725114Written as Tetrodotoxin
- Tetrodotoxin Open-label Efficacy and Safety Continuation StudyCompletedPhase 3Wex Pharmaceuticals Inc.NCT00726011Written as Tetrodotoxin
- Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy VolunteersCompletedPhase 1Wex Pharmaceuticals Inc.NCT01527734Written as Tetrodotoxin
Codes
What other systems call Tetrodotoxin · ClinicalTrials.gg INT008298
- MeSH (NLM) D013779TetrodotoxinOne source ClinicalTrials.gov
- UNII (FDA) 3KUM2721U9TETRODOTOXINOne source FDA
- NCI Thesaurus C78845TetrodotoxinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D013779 | Tetrodotoxin | One source ClinicalTrials.gov |
| UNII (FDA) | 3KUM2721U9 | TETRODOTOXIN | One source FDA |
| NCI Thesaurus | C78845 | Tetrodotoxin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.